Nephrology Dialysis Transplantation

Frontmatter:

Alex M. Davison

Foreword
Nephrol. Dial. Transplant. 17: 1; doi:10.1093/ndt/17.suppl_7.1 [PDF] [Request Permissions]  

Michele Kessler

Introduction
Nephrol. Dial. Transplant. 17: 2; doi:10.1093/ndt/17.suppl_7.2 [PDF] [Request Permissions]  

Guideline development
Nephrol. Dial. Transplant. 17: 3-4; doi:10.1093/ndt/17.suppl_7.3 [PDF] [Request Permissions]  

Abbreviations
Nephrol. Dial. Transplant. 17: 5-6; doi:10.1093/ndt/17.suppl_7.5 [PDF] [Request Permissions]  

SECTION I: Measurement of renal function, when to refer and when to start dialysis:

I.1 Measurement of renal function
Nephrol. Dial. Transplant. 17: 7-9; doi:10.1093/ndt/17.suppl_7.7 [Abstract] [PDF] [Request Permissions]  

I.2 When to refer to a nephrology clinic
Nephrol. Dial. Transplant. 17: 9-10; doi:10.1093/ndt/17.suppl_7.9 [Abstract] [PDF] [Request Permissions]  

I.3 When to start dialysis
Nephrol. Dial. Transplant. 17: 10-11; doi:10.1093/ndt/17.suppl_7.10 [Abstract] [PDF] [Request Permissions]  

I.4 Measurement of residual renal function in HD
Nephrol. Dial. Transplant. 17: 11-14; doi:10.1093/ndt/17.suppl_7.11 [Abstract] [PDF] [Request Permissions]  

Appendix I
Nephrol. Dial. Transplant. 17: 14-15; doi:10.1093/ndt/17.suppl_7.14 [PDF] [Request Permissions]  

Appendix II
Nephrol. Dial. Transplant. 17: 15; doi:10.1093/ndt/17.suppl_7.15 [PDF] [Request Permissions]  

SECTION II: Haemodialysis adequacy:

II.1 Haemodialysis dose quantification: small solutes
Nephrol. Dial. Transplant. 17: 17-21; doi:10.1093/ndt/17.suppl_7.17 [Abstract] [PDF] [Request Permissions]  

II.2 Haemodialysis dose quantification: middle molecules (MM)
Nephrol. Dial. Transplant. 17: 21-23; doi:10.1093/ndt/17.suppl_7.21 [Abstract] [PDF] [Request Permissions]  

II.3 Haemodialysis dose and residual renal function (Kr)
Nephrol. Dial. Transplant. 17: 24; doi:10.1093/ndt/17.suppl_7.24 [Abstract] [PDF] [Request Permissions]  

II.4 Monitoring of treatment
Nephrol. Dial. Transplant. 17: 24-25; doi:10.1093/ndt/17.suppl_7.24-a [Abstract] [PDF] [Request Permissions]  

II.5 Dialysis schedules
Nephrol. Dial. Transplant. 17: 25-31; doi:10.1093/ndt/17.suppl_7.25 [Abstract] [PDF] [Request Permissions]  

SECTION III: Biocompatibility:

III.1 Biochemical reactions subsequent to complement and leukocyte activation
Nephrol. Dial. Transplant. 17: 32-34; doi:10.1093/ndt/17.suppl_7.32 [Abstract] [PDF] [Request Permissions]  

III.2 Clinical morbidity and mortality in response to complement and leukocyte activation
Nephrol. Dial. Transplant. 17: 34-37; doi:10.1093/ndt/17.suppl_7.34 [Abstract] [PDF] [Request Permissions]  

III.3 Spallation/release
Nephrol. Dial. Transplant. 17: 37; doi:10.1093/ndt/17.suppl_7.37 [Abstract] [PDF] [Request Permissions]  

III.4 Reactions to membranes and other dialyzer-related material
Nephrol. Dial. Transplant. 17: 37-38; doi:10.1093/ndt/17.suppl_7.37-a [Abstract] [PDF] [Request Permissions]  

III.5 Shear stress/haemolysis
Nephrol. Dial. Transplant. 17: 38-44; doi:10.1093/ndt/17.suppl_7.38 [Abstract] [PDF] [Request Permissions]  

SECTION IV: Dialysis fluid purity:

IV.1 Water treatment system
Nephrol. Dial. Transplant. 17: 45-46; doi:10.1093/ndt/17.suppl_7.45 [Abstract] [PDF] [Request Permissions]  

IV.2 Technical design of the water treatment system
Nephrol. Dial. Transplant. 17: 46-47; doi:10.1093/ndt/17.suppl_7.46 [Abstract] [PDF] [Request Permissions]  

IV.3 Water treatment monitoring and maintenance
Nephrol. Dial. Transplant. 17: 47-49; doi:10.1093/ndt/17.suppl_7.47 [Abstract] [PDF] [Request Permissions]  

IV.4 Haemodialysishyphen;proportioning machine
Nephrol. Dial. Transplant. 17: 49-50; doi:10.1093/ndt/17.suppl_7.49 [Abstract] [PDF] [Request Permissions]  

IV.5 Electrolytic concentrates
Nephrol. Dial. Transplant. 17: 50-51; doi:10.1093/ndt/17.suppl_7.50 [Abstract] [PDF] [Request Permissions]  

IV.6 Dialysis fluid purity: implications in the haemocompatibility network system
Nephrol. Dial. Transplant. 17: 51-54; doi:10.1093/ndt/17.suppl_7.51 [Abstract] [PDF] [Request Permissions]  

Appendix: Water purification methods
Nephrol. Dial. Transplant. 17: 54-61; doi:10.1093/ndt/17.suppl_7.54 [PDF] [Request Permissions]  

Appendix: Quality assurance process
Nephrol. Dial. Transplant. 17: 60-62; doi:10.1093/ndt/17.suppl_7.60 [PDF] [Request Permissions]  

SECTION V: Chronic intermittent haemodialysis and prevention of clotting in the extracorporal syste:

V.1 Haemodialysis and prevention of system clotting
Nephrol. Dial. Transplant. 17: 63; doi:10.1093/ndt/17.suppl_7.63 [PDF] [Request Permissions]  

V.2 Prevention of clotting in the HD patient with normal bleeding risk
Nephrol. Dial. Transplant. 17: 64-66; doi:10.1093/ndt/17.suppl_7.64 [PDF] [Request Permissions]  

V.3 Prevention of clotting in the HD patient with elevated bleeding risk
Nephrol. Dial. Transplant. 17: 66-67; doi:10.1093/ndt/17.suppl_7.66 [PDF] [Request Permissions]  

V.4 Heparin-induced thrombocytopenia
Nephrol. Dial. Transplant. 17: 67; doi:10.1093/ndt/17.suppl_7.67 [Abstract] [PDF] [Request Permissions]  

V.5 Side effects of heparin
Nephrol. Dial. Transplant. 17: 67-71; doi:10.1093/ndt/17.suppl_7.67-a [Abstract] [PDF] [Request Permissions]  

SECTION VI: Haemodialysis-associated infection:

VI.1 Prevention of infection: management of impairment of the host defence
Nephrol. Dial. Transplant. 17: 73-74; doi:10.1093/ndt/17.suppl_7.73 [Abstract] [PDF] [Request Permissions]  

VI.2 Prevention of infection: management of host colonization by Staphylococcus aureus
Nephrol. Dial. Transplant. 17: 74-75; doi:10.1093/ndt/17.suppl_7.74 [Abstract] [PDF] [Request Permissions]  

VI.3 Prevention of infection: management of the vascular access
Nephrol. Dial. Transplant. 17: 75-76; doi:10.1093/ndt/17.suppl_7.75 [PDF] [Request Permissions]  

VI.4. Treatment of vascular access infection
Nephrol. Dial. Transplant. 17: 76-77; doi:10.1093/ndt/17.suppl_7.76 [PDF] [Request Permissions]  

VI.5 Prevention and management of TB in HD patients
Nephrol. Dial. Transplant. 17: 77-78; doi:10.1093/ndt/17.suppl_7.77 [PDF] [Request Permissions]  

VI.6 Prevention and management of HBV, HCV and HIV in HD patients
Nephrol. Dial. Transplant. 17: 78-81; doi:10.1093/ndt/17.suppl_7.78 [PDF] [Request Permissions]  

VI.7 Vaccine recommendations for patients on chronic HD (except HB vaccination)
Nephrol. Dial. Transplant. 17: 81-87; doi:10.1093/ndt/17.suppl_7.81 [PDF] [Request Permissions]  

SECTION VII: Vascular disease and risk factors:

VII.1 Assessment of cardiovascular risk factors
Nephrol. Dial. Transplant. 17: 88; doi:10.1093/ndt/17.suppl_7.88 [Abstract] [PDF] [Request Permissions]  

VII.2 Dyslipidaemia
Nephrol. Dial. Transplant. 17: 88-95; doi:10.1093/ndt/17.suppl_7.88-a [PDF] [Request Permissions]  

VII.3 Hyperphosphataemia and calcium-phosphorus ion product
Nephrol. Dial. Transplant. 17: 95-96; doi:10.1093/ndt/17.suppl_7.95 [Abstract] [PDF] [Request Permissions]  

VII.4 Emerging risk factors
Nephrol. Dial. Transplant. 17: 96-100; doi:10.1093/ndt/17.suppl_7.96 [PDF] [Request Permissions]  

VII.5 Microinflammatory state
Nephrol. Dial. Transplant. 17: 100-109; doi:10.1093/ndt/17.suppl_7.100 [PDF] [Request Permissions]  

Backmatter:

Biographical notes
Nephrol. Dial. Transplant. 17: 110-111; doi:10.1093/ndt/17.suppl_7.110 [PDF] [Request Permissions]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.